<DOC>
	<DOCNO>NCT00003607</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . It yet know whether radiation therapy prostate pelvis effective radiation therapy prostate alone treat prostate cancer . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy prostate without radiation pelvis treat patient stage I , stage II , stage III prostate cancer .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Stage I , Stage II , Stage III Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival without recurrence overall survival patient stage I , II , III adenocarcinoma prostate receive radiotherapy prostate without radiotherapy pelvis . - Compare toxic effect two regimen patient . - Compare quality life patient treat regimen . - Determine prognostic factor progression patient . - Analyze site relapse ( prostate , pelvic lymph node , metastasis ) case progression patient . OUTLINE : This randomize , multicenter study . Patients stratify participate center prognostic group ( poor vs good prognosis ) . Patients randomize one two treatment arm . - Arm I : Patients receive pelvic irradiation plus local prostate irradiation . - Arm II : Patients receive local prostate irradiation . Radiotherapy arm administer 5 day week 7 week . Quality life assess therapy , 12 month therapy , annually thereafter . Patients follow 2 6 month every 6 month thereafter . PROJECTED ACCRUAL : A total 450 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven adenocarcinoma prostate Stage I ( T1b T1c , N0 , M0 ) Stage II ( T2 , N0 , M0 ) Stage III ( T3 , N0 , M0 ) Poor prognosis ( high risk lymph node invasion ) define meet least 1 follow criterion : Gleason score least 7 Prostatespecific antigen ( PSA ) least 3 time upper limit normal ( ULN ) T3 OR Good prognosis define meet 1 follow criterion : T1b T2 T1c Gleason score less 7 PSA less 3 time ULN No metastases bone scans chest xray PATIENT CHARACTERISTICS : Age : 75 Performance status : Karnofsky 70100 % Life expectancy : More 10 year Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No malignancy within past 10 year except basal cell skin cancer No adenopathies PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : At least 26 month since prior hormonal therapy , duration great 48 month No concurrent luteinizing hormonereleasing hormone agonists No concurrent antiandrogen therapy No concurrent hormonal therapy highrisk group Radiotherapy : No prior pelvic radiotherapy Surgery : No prior lymphadenectomy No prior surgical castration No prior prostatectomy At least 1 month since prior transurethral resection</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>